These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6328965)

  • 1. Estimation of angiotensin II receptor activity in chronic congestive heart failure.
    Cody RJ; Covit AB; Schaer GL; Laragh JH
    Am Heart J; 1984 Jul; 108(1):81-9. PubMed ID: 6328965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular angiotensin receptors and their role in blood pressure control.
    Thurston H
    Am J Med; 1976 Nov; 61(5):768-78. PubMed ID: 185902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II contributes to cerebral vasodilatation during hypoxia in the rabbit.
    Maktabi MA; Todd MM; Stachovic G
    Stroke; 1995 Oct; 26(10):1871-6. PubMed ID: 7570741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.
    Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH
    Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immediate pressor response to saralasin: a measure of the degree of angiotensin II vascular receptor vacancy.
    Wallace JM; Case DB; Laragh JH; Sealey JE; Keim HJ; Drayer JI
    Trans Assoc Am Physicians; 1977; 90():300-12. PubMed ID: 205983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.
    Cody RJ; Covit AB; Schaer GL; Laragh JH
    J Am Coll Cardiol; 1983 Apr; 1(4):1154-9. PubMed ID: 6187789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure.
    Cody RJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S58-65. PubMed ID: 2422494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug suppression of the angiotensin system in congestive heart failure.
    Sullivan JM
    Annu Rev Med; 1983; 34():169-77. PubMed ID: 6190432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II blockade in congestive heart failure.
    Turini GA; Brunner HR; Ferguson RK; Rivier JL; Gavras H
    Arch Int Pharmacodyn Ther; 1978 May; 233(1):166-76. PubMed ID: 686905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal responses to angiotensin blockade. Comparison between receptor antagonism and converting enzyme inhibition.
    Johnston CI; Millar JA; Casley DJ; McGrath BP; Matthews PG
    Circ Res; 1980 Jun; 46(6 Pt 2):I128-34. PubMed ID: 6247084
    [No Abstract]   [Full Text] [Related]  

  • 11. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M; Suzuki H; Naitoh M; Matsumoto A; Kageyama Y; Tsujimoto G; Saruta T
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
    Turini GA; Waeber B; Brunner HR
    Eur Heart J; 1983 Jan; 4 Suppl A():189-97. PubMed ID: 6301835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade.
    Turini GA; Brunner HR; Ferguson RK; Rivier JL; Gavras H
    Br Heart J; 1978 Oct; 40(10):1134-42. PubMed ID: 708515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baroreceptor reflex in the rat after converting enzyme inhibition or angiotensin receptor blockade.
    Coleman TG; Salgado MC; Bengis RG; Davis MH; Dent AC
    Clin Exp Pharmacol Physiol; 1981 Jan; 8(1):79-82. PubMed ID: 6258832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of converting enzyme inhibition and angiotensin receptor blockade on the vasoconstriction mediated by alpha 1-and alpha 2-adrenoceptor stimulation in pithed normotensive rats.
    de Jonge A; Knape JT; van Meel JC; Kalkman HO; Wilffert B; Thoolen MJ; Timmermanns PB; van Zwieten PA
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Dec; 321(4):309-13. PubMed ID: 6188064
    [No Abstract]   [Full Text] [Related]  

  • 16. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
    Cody RJ
    Drugs; 1984 Aug; 28(2):144-69. PubMed ID: 6205842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.
    Case DB; Wallace JM; Keim HJ; Sealey JE; Laragh JH
    Am J Med; 1976 May; 60(6):825-36. PubMed ID: 1020762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation by angiotensin II of its receptors in resistance blood vessels.
    Gunther S; Gimbrone MA; Alexander RW
    Nature; 1980 Sep; 287(5779):230-2. PubMed ID: 6253796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous angiotensin II facilitates sympathetically mediated hemodynamic responses in pithed rats.
    Kaufman LJ; Vollmer RR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):128-34. PubMed ID: 3900340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II and not sodium status is the major determinant of the agonistic/antagonistic balance of saralasin's actions.
    Fagard R; Amery A; Lijnen P
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():75s-78s. PubMed ID: 7004740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.